Risk factors for postoperative recurrence of intraductal papillary mucinous neoplasms of the pancreas based on a long-term follow-up study: proposals for follow-up strategies
Correction(s) for this article
-
Erratum
- Volume 24Issue 1Journal of Hepato-Biliary-Pancreatic Sciences
- pages: 72-73
- First Published online: February 3, 2017
Tatsuji Yogi
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
Department of Infectious, Respiratory, and Digestive Medicine, Control and Prevention of Infectious Diseases (First Department of Internal Medicine), Faculty of Medicine, University of the Ryukyus, Okinawa, Japan
Search for more papers by this authorCorresponding Author
Susumu Hijioka
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
Correspondence to: Susumu Hijioka, Department of Gastroenterology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.
Email: [email protected]
Search for more papers by this authorHiroshi Imaoka
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorNobumasa Mizuno
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorKazuo Hara
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorMasahiro Tajika
Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorTsutomu Tanaka
Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorMakoto Ishihara
Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorYasuhiro Shimizu
Department of Gastrointestinal Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorWaki Hosoda
Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorYasushi Yatabe
Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorYasumasa Niwa
Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorKenichi Yoshimura
Innovative Clinical Research Center, Kanazawa University, Kanazawa, Japan
Search for more papers by this authorVikram Bhatia
Department of Hepatology, Institute of Liver and Biliary Sciences, Delhi, India
Search for more papers by this authorJiro Fujita
Department of Infectious, Respiratory, and Digestive Medicine, Control and Prevention of Infectious Diseases (First Department of Internal Medicine), Faculty of Medicine, University of the Ryukyus, Okinawa, Japan
Search for more papers by this authorKenji Yamao
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorTatsuji Yogi
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
Department of Infectious, Respiratory, and Digestive Medicine, Control and Prevention of Infectious Diseases (First Department of Internal Medicine), Faculty of Medicine, University of the Ryukyus, Okinawa, Japan
Search for more papers by this authorCorresponding Author
Susumu Hijioka
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
Correspondence to: Susumu Hijioka, Department of Gastroenterology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.
Email: [email protected]
Search for more papers by this authorHiroshi Imaoka
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorNobumasa Mizuno
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorKazuo Hara
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorMasahiro Tajika
Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorTsutomu Tanaka
Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorMakoto Ishihara
Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorYasuhiro Shimizu
Department of Gastrointestinal Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorWaki Hosoda
Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorYasushi Yatabe
Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorYasumasa Niwa
Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorKenichi Yoshimura
Innovative Clinical Research Center, Kanazawa University, Kanazawa, Japan
Search for more papers by this authorVikram Bhatia
Department of Hepatology, Institute of Liver and Biliary Sciences, Delhi, India
Search for more papers by this authorJiro Fujita
Department of Infectious, Respiratory, and Digestive Medicine, Control and Prevention of Infectious Diseases (First Department of Internal Medicine), Faculty of Medicine, University of the Ryukyus, Okinawa, Japan
Search for more papers by this authorKenji Yamao
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorAbstract
Background
The aim of this study was to examine the associations between postoperative clinicopathological features of intraductal papillary mucinous neoplasm (IPMN) and recurrence over a long follow-up period.
Methods
We retrospectively assessed 153 IPMN patients who underwent resection.
Results
The resected tumors showed low/intermediate-grade dysplasia (LGD/IGD), high-grade dysplasia (HGD), T1a (stromal invasion ≤5 mm), and invasive intraductal papillary mucinous carcinoma (IPMC), in 54.9%, 22.2%, 4.6%, and 18.3% of patients, respectively. The median follow-up period after surgery was 46.4 (6.0–216.3) months, with an overall recurrence rate of 17.0%; the recurrence rates by histological type were 6.0%, 5.9%, 42.9%, and 57.1% for LGD/IGD, HGD, T1a, and invasive IPMC, respectively. Multivariate analysis revealed that recurrences related with tumor location, mural nodule size, presence of invasive cancer, lymph node metastasis, IPMN in the remnant pancreas, and main pancreatic duct dilatation after surgery. Recurrence occurred within the remnant pancreas in all LGD-T1a patients and as extrapancreatic metastasis in all patients with invasive IPMC. Of the total recurrences, 15.4% occurred over 5 years postoperatively.
Conclusions
The postoperative follow-up protocol for patients with LGD-T1a should be similar to non-resected IPMN, and that for invasive IPMC should be the same as for pancreatic ductal adenocarcinoma patients.
References
- 1Ohhashi K, Murakami Y, Maruyama M, Takekoshi T, Ohta H, Ohhashi I. Four cases of mucous secreting pancreatic cancer (in Japanese). Prog Dig Endosc. 1982; 20: 348–51.
- 2Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006; 6: 17–32.
- 3Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012; 12: 183–97.
- 4Kang MJ, Jang JY, Lee KB, Chang YR, Kwon W, Kim SW, et al. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Ann Surg. 2014; 260: 356–63.
- 5Park J, Lee KT, Jang TH, Seo YW, Lee KH, Lee JK, et al. Risk factors associated with the postoperative recurrence of intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2011; 40: 46–51.
- 6Passot G, Lebeau R, Hervieu V, Ponchon T, Pilleul F, Adham M, et al. Recurrences after surgical resection of intraductal papillary mucinous neoplasm of the pancreas: a single-center study of recurrence predictive factors. Pancreas. 2012; 41: 137–41.
- 7Winner M, Epelboym I, Remotti H, Lee JL, Schrope BA, Chabot JA, et al. Predictors of recurrence in intraductal papillary mucinous neoplasm: experience with 183 pancreatic resections. J Gastrointest Surg. 2013; 17: 1618–26.
- 8Nara S, Shimada K, Sakamoto Y, Esaki M, Kosuge T, Hiraoka N. Clinical significance of frozen section analysis during resection of intraductal papillary mucinous neoplasm: should a positive pancreatic margin for adenoma or borderline lesion be resected additionally? J Am Coll Surg. 2009; 209: 614–21.
- 9Ohtsuka T, Kono H, Tanabe R, Nagayoshi Y, Mori Y, Sadakari Y, et al. Follow-up study after resection of intraductal papillary mucinous neoplasm of the pancreas; special references to the multifocal lesions and development of ductal carcinoma in the remnant pancreas. Am J Surg. 2012; 204: 44–8.
- 10Wada K, Kozarek RA, Traverso LW. Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas. Am J Surg. 2005; 189: 632–6.
- 11Nara S, Shimada K, Kosuge T, Kanai Y, Hiraoka N. Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic study of 104 intraductal papillary-mucinous neoplasms. Am J Surg Pathol. 2008; 32: 243–55.
- 12Nagai K, Doi R, Kida A, Kami K, Kawaguchi Y, Ito T, et al. Intraductal papillary mucinous neoplasms of the pancreas: clinicopathologic characteristics and long-term follow-up after resection. World J Surg. 2008; 32: 271–8.
- 13Schnelldorfer T, Sarr MG, Nagorney DM, Zhang L, Smyrk TC, Qin R, et al. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008; 143: 639–46.
- 14Chari ST, Yadav D, Smyrk TC, DiMagno EP, Miller LJ, Raimondo M, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology. 2002; 123: 1500–7.
- 15Sugiura H, Kondo S, Islam HK, Ito K, Ono K, Morikawa T, et al. Clinicopathologic features and outcomes of intraductal papillary-mucinous tumors of the pancreas. Hepatogastroenterology. 2001; 49: 263–7.
- 16Niedergethmann M, Grützmann R, Hildenbrand R, Dittert D, Aramin N, Franz M, et al. Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience. World J Surg. 2008; 32: 2253–60.
- 17Kim SC, Park KT, Lee YJ, Lee SS, Seo DW, Lee SK, et al. Intraductal papillary mucinous neoplasm of the pancreas: clinical characteristics and treatment outcomes of 118 consecutive patients from a single center. J Hepatobiliary Pancreat Surg. 2008; 15: 183–8.
- 18Furukawa T, Hatori T, Fujita I, Yamamoto M, Kobayashi M, Ohike N, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut. 2011; 60: 509–16.
- 19Turrini O, Waters JA, Schnelldorfer T, Lillemoe KD, Yiannoutsos CT, Farnell MB, et al. Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy. HPB (Oxford). 2010; 12: 447–55.
- 20Miller JR, Meyer JE, Waters JA, Al-Haddad M, Dewitt J, Sherman S, et al. Outcome of the pancreatic remnant following segmental pancreatectomy for non-invasive intraductal papillary mucinous neoplasm. HPB (Oxford). 2011; 13: 759–66.
- 21Marchegiani G, Mino-Kenudson M, Sahora K, Morales-Oyarvide V, Thayer S, Ferrone C, et al. IPMN involving the main pancreatic duct: biology, epidemiology, and long-term outcomes following resection. Ann Surg. 2015; 261: 976–83.
- 22Fujii T, Kato K, Kodera Y, Kanda M, Nagai S, Yamada S, et al. Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas. Surgery. 2010; 148: 285–90.
- 23Salvia R, Fernández-del Castillo C, Bassi C, Thayer SP, Falconi M, Mantovani W, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004; 239: 678–87.
- 24Maguchi H, Tanno S, Mizuno N, Hanada K, Kobayashi G, Hatori T, et al. Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas: a multicenter study in Japan. Pancreas. 2011; 40: 364–70.
- 25Sawai Y, Yamao K, Bhatia V, Chiba T, Mizuno N, Sawaki A, et al. Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms. Endoscopy. 2010; 42: 1077–84.
- 26White R, D'Angelica M, Katabi N, Tang L, Klimstra D, Fong Y, et al. Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm. J Am Coll Surg. 2007; 204: 987–93.
- 27Tada M, Kawabe T, Arizumi M, Togawa O, Matsubara S, Yamamoto N, et al. Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol. 2006; 4: 1265–70.
- 28Tanno S, Nakano Y, Koizumi K, Sugiyama Y, Nakamura K, Sasajima J, et al. Pancreatic ductal adenocarcinomas in long-term follow-up patients with branch duct intraductal papillary mucinous neoplasms. Pancreas. 2010; 39: 36–40.
- 29Maire F, Hammel P, Terris B, Paye F, Scoazec JY, Cellier C, et al. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut. 2002; 51: 717–22.
- 30Yamaguchi K, Kanemitsu S, Hatori T, Maguchi H, Shimizu Y, Tada M, et al. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas. 2011; 40: 571–80.
- 31Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB III, Casper ES, et al. Pancreatic adenocarcinoma, Version 2.2012 featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012; 10: 703–13.
Citing Literature
